Advancements in application of continuous glucose monitoring in patients with chronic kidney disease and diabetes

doi:10.3877/cma.j.issn.1674-0785.2024.01.012

Abstract

Abstract:

Diabetes is gradually becoming one of the leading causes of chronic kidney disease (CKD). Glycemic control is closely related to renal outcomes and the risk of microvascular complications in diabetes patients. However, laboratory biomarkers such as glycated hemoglobin cannot fully capture the dynamic blood glucose abnormalities associated with the disease. The kidney plays a crucial role in maintaining the body's glucose homeostasis, and the unique pathophysiological characteristics of glucose metabolism in patients with CKD can also affect the accuracy of traditional biomarkers, leading to biased results and increasing the challenge of glycemic control in patients. Continuous glucose monitoring (CGM), by providing multiple parameters such as average glucose levels, glycemic variability, and the time in target ranges, has revealed significant deviations in blood glucose levels in patients with CKD, although studies in this population are limited. Treatments like hemodialysis and peritoneal dialysis also impact blood glucose fluctuations. CGM has the potential to improve the quality of glycemic monitoring and control in the CKD population, but further research is needed to confirm its accuracy and optimal usage.

Key words: Chronic kidney disease, Continuous glucose monitoring, Diabetes

Caijun Yuan, Ping Wen, Lingling Xu. Advancements in application of continuous glucose monitoring in patients with chronic kidney disease and diabetes[J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(01): 79-82.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2024.01.012

https://zhlcyszz.cma-cmc.com.cn/EN/Y2024/V18/I01/79

References 35

1	United States Renal Data System. 2022 USRDS Annual Data Report: Epidemiology of kidney disease in the United States[J]. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2022.
2	Wang L, Xu X, Zhang M, et al. Prevalence of chronic kidney disease in China: results from the sixth China chronic disease and risk factor surveillance[J]. JAMA Intern Med, 2023, 183(4): 298-310.
3	Drechsler C, Krane V, Ritz E, et al. Glycemic control and cardiovascular events in diabetic hemodialysis patients[J]. Circulation, 2009, 120(24): 2421-2428.
4	Thomas MC, Brownlee M, Susztak K, et al. Diabetic kidney disease[J]. Nat Rev Dis Primers, 2015, 1: 15018.
5	Mather A, Pollock C. Glucose handling by the kidney[J]. Kidney Int Suppl, 2011(120): S1-S6.
6	Hassanein M, Shafi T. Assessment of glycemia in chronic kidney disease[J]. BMC Med, 2022, 20(1): 117.
7	Galindo RJ, Beck RW, Scioscia MF, et al. Glycemic monitoring and management in advanced chronic kidney disease[J]. Endocr Rev, 2020, 41(5): 756-774.
8	Koga M. 1,5-Anhydroglucitol and glycated albumin in glycemia[J]. Adv Clin Chem, 2014, 64: 269-301.
9	Perlman JE, Gooley TA, McNulty B, et al. HbA1c and glucose management indicator discordance: A real-world analysis[J]. Diabetes Technol Ther, 2021, 23(4): 253-258.
10	Jung M, Warren B, Grams M, et al. Performance of non-traditional hyperglycemia biomarkers by chronic kidney disease status in older adults with diabetes: Results from the atherosclerosis risk in communities study[J]. J Diabetes, 2018, 10(4): 276-285.
11	Ng JM, Cooke M, Bhandari S, et al. The effect of iron and erythropoietin treatment on the A1C of patients with diabetes and chronic kidney disease[J]. Diabetes Care, 2010, 33(11): 2310-2313.
12	Zelnick LR, Batacchi ZO, Ahmad I, et al. Continuous glucose monitoring and use of alternative markers To assess glycemia in chronic kidney disease[J]. Diabetes Care, 2020, 43(10): 2379-2387.
13	Navaneethan SD, Zoungas S, Caramori ML, et al. Diabetes management in chronic kidney disease: synopsis of the 2020 Kdigo clinical practice guideline[J]. Ann Intern Med, 2021, 174(3): 385-394.
14	ElSayed NA, Aleppo G, Aroda VR, et al. 6. Glycemic targets: standards of care in diabetes-2023[J]. Diabetes Care, 2023, 46(Suppl 1): S97-S110.
15	Ahmad I, Zelnick LR, Batacchi Z, et al. Hypoglycemia in people with type 2 diabetes and CKD[J]. Clin J Am Soc Nephrol, 2019, 14(6): 844-853.
16	Kazempour-Ardebili S, Lecamwasam VL, Dassanyake T, et al. Assessing glycemic control in maintenance hemodialysis patients with type 2 diabetes[J]. Diabetes Care, 2009, 32(7): 1137-1142.
17	Gai M, Merlo I, Dellepiane S, et al. Glycemic pattern in diabetic patients on hemodialysis: continuous glucose monitoring (CGM) analysis[J]. Blood Purif, 2014, 38(1): 68-73.
18	刘向阳, 郭航, 郭俊, 等. 应用扫描式葡萄糖监测系统监测透析治疗的合并糖尿病肾脏病的2型糖尿病患者血糖波动的价值[J]. 中华糖尿病杂志, 2021, 13(10): 960-965.
19	Joubert M, Fourmy C, Henri P, et al. Effectiveness of continuous glucose monitoring in dialysis patients with diabetes: the Dialydiab pilot study[J]. Diabetes Res Clin Pract, 2015, 107(3): 348-354.
20	Mirani M, Berra C, Finazzi S, et al. Inter-day glycemic variability assessed by continuous glucose monitoring in insulin-treated type 2 diabetes patients on hemodialysis[J]. Diabetes Technol Ther, 2010, 12(10): 749-753.
21	Williams J, Gilchrist M, Strain WD, et al. 24-h Glycaemic profiles in peritoneal dialysis patients and non-dialysis controls with advanced kidney disease[J]. Perit Dial Int, 2022, 42(5): 497-504.
22	Aouad LJ, Clayton P, Wyburn KR, et al. Evolution of glycemic control and variability after kidney transplant[J]. Transplantation, 2018, 102(9):1563-1568.
23	Diabetes C, Complications Trial Research G, Nathan DM, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus[J]. N Engl J Med, 1993, 329(14): 977-986.
24	Diabetes C, Complications Trial /Epidemiology of Diabetes I, Complications Research G, et al. Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC[J]. Diabetes, 2015, 64(2): 631-642.
25	Group DER, de Boer IH, Sun W, et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes[J]. N Engl J Med, 2011, 365(25): 2366-2376.
26	Fang HJ, Zhou YH, Tian YJ, et al. Effects of intensive glucose lowering in treatment of type 2 diabetes mellitus on cardiovascular outcomes: A meta-analysis of data from 58,160 patients in 13 randomized controlled trials[J]. Int J Cardiol, 2016, 218: 50-58.
27	Gubitosi-Klug RA, Braffett BH, White NH, et al. Risk of severe hypoglycemia in type 1 diabetes over 30 years of follow-up in the DCCT/EDIC study[J]. Diabetes Care, 2017, 40(8): 1010-1016.
28	Ramirez SP, McCullough KP, Thumma JR, et al. Hemoglobin A(1c) levels and mortality in the diabetic hemodialysis population: findings from the Dialysis Outcomes and Practice Patterns Study (DOPPS)[J]. Diabetes Care, 2012, 35(12): 2527-2532.
29	Kepenekian L, Smagala A, Meyer L, et al. Continuous glucose monitoring in hemodialyzed patients with type 2 diabetes: a multicenter pilot study[J]. Clin Nephrol, 2014, 82(4): 240-246.
30	王丽纯, 张晓菲, 胡文利, 等. 血糖波动与危重症患者预后相关性的临床研究[J/OL]. 中华临床医师杂志(电子版), 2011, 5(24): 7291-7294.
31	翟迎九, 郭美姿, 吕清, 等. 血糖波动对老年糖尿病患者氧化应激指标及胰岛β细胞功能的影响[J/OL]. 中华临床医师杂志(电子版), 2018, 12(9): 500-503.
32	宫倩倩, 吕肖锋, 张名扬, 等. 血糖波动对2型糖尿病患者下肢血管病变的影响[J/OL]. 中华临床医师杂志(电子版), 2013(23): 10691-10695.
33	Zhou JJ, Koska J, Bahn G, et al. Fasting glucose variation predicts microvascular risk in Accord and Vadt[J]. J Clin Endocrinol Metab, 2021, 106(4): 1150-1162.
34	Lu J, Ma X, Zhou J, et al. Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes[J]. Diabetes Care, 2018, 41(11): 2370-2376.
35	Mayeda L, Katz R, Ahmad I, et al. Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease[J]. BMJ Open Diabetes Res Care, 2020, 8(1): e000991.

[1]	Jinmei He, Lixue Yin, Jing Tan, Wenjun Zhang, Rui Wang, Mei Ren, Mingjiao Liao. Evaluation of potential left ventricular systolic dysfunction in patients with type 2 diabetes mellitus using ultrasonic myocardial work technology [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(10): 1029-1035.
[2]	Hui Wang, Baorui Xue, Gongchi Li, Huizhen Liu, Xia Lei, Binghui Li. Analysis of influencing factors of lower extremity arteriosclerosis in patients with type 2 diabetes mellitus [J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2024, 19(02): 147-152.
[3]	Rongqin Feng, Peng Wang, Yu Li, He Lu, Xiaozhi Bai, Juntao Han. Research progress on the role of antimicrobial peptides in diabetic wound healing [J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2024, 19(01): 78-82.
[4]	Jian Mao. Pathogen distribution of community acquired pneumonia in elderly patients with diabetes and the predictive value of fasting blood glucose and glycosylated hemoglobin [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2023, 17(06): 408-415.
[5]	Shuai Zhao, Wei Wang, Ruiqi Li, Jiajie Zhou, Daorong Wang. Clinical efficacy and influencing factors of 3D laparoscopic sleeve gastrectomy for the treatment of obesity combined with type 2 diabetes mellitus [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(02): 146-149.
[6]	Dun Liu, Sheng Pan. Effect of different approaches of laparoscopic sleeve gastrectomy for obesity with type 2 diabetes mellitus [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(02): 150-154.
[7]	Branch of Organ Transplant of Chinese Medical Association, Branch of Organ Transplant Physicians of Chinese Medical Doctor Association. Clinical practice guidelines for kidney injury management of liver transplant recipients in China (2023 edition) [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(06): 321-331.
[8]	Ting Yan, Yaoyao Liang, Jin Chen. Current advances in stem cells derived insulin-producing cells for diabetes mellitus therapy [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(06): 355-362.
[9]	Meng Wang, Ruimin Zhang, Bo Fu, Qian Wang, Zheyi Dong, Xiangmei Chen. Progress in etiology and internal medical treatment of nocturia in diabetic patients [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(01): 46-49.
[10]	Yan Huang, Xiaowei Liu, Chunling Yang, Ye Lan. Clinical characteristics and correlation between blood glucose metabolism and severity of acute pancreatitis with diabetes [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 439-442.
[11]	Zhengying Zhang, Yang Ju, Xiaoning Liu. Effect of oral metformin on postoperative recurrence of type 2 diabetes mellitus with colorectal adenoma [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 485-488.
[12]	Nianyu Xue, Shengmin Zhang, Lingheng Wu, Lei Sha, Lanyue Tong, Cuiqin Shen, Zhaojun Li, Lianfang Du. Effect of serum bilirubin on myocardial function in patients with type 2 diabetes before cardiac structural changes [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(09): 1004-1009.
[13]	Cheng Yi, Wei Wei, Yuliang Zhao. The last piece of picture puzzle: conceptual evolution of acute kidney disease [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(08): 906-910.
[14]	Guoxiao Xie, Lingxia Zhao, Xuehua Xue. Application of chronic disease management model in diabetes community management [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(05): 587-590.
[15]	Ting Luo, Lingzhi Qiu, Dong Yi, Hua Yan. Research progress on the relationship between mitochondrial dysfunction and cardiovascular disease, ischemic stroke and chronic kidney disease [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2024, 18(01): 60-63.

Please choose a citation manager

Content to export